Azenta (AZTA) AI Stock Analysis

• Market Cap: $1.79B
• Dividend Yield: N/A
• Average Volume (3M): 587.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: -9.49%
• EPS Growth: 58.97%
• Country: US
• Employees: 3,000
• Sector: N/A
• Sector Strength: N/A
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 45,989,580
• 10 Day Avg. Volume: 463,449
• 30 Day Avg. Volume: 587,594
• PEG Ratio: 0.38
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 2.21
• P/FCF Ratio: 34.28
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 2.47
• Enterprise Value/Gross Profit: 5.35
• Enterprise Value/Ebitda: 36.68
• 1Y Price Target: $41.83
• Price Target Upside: 19.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: $41.00 ▲(16.98% Upside)

AZTA scores as moderately attractive primarily due to improving technical momentum and a constructive outlook for FY2026 (margin expansion and modest growth) backed by a solid balance sheet and shareholder-friendly actions. The score is held back by weaker financial performance (losses and revenue pressure) and a negative P/E that reflects ongoing profitability risk.

Azenta Business Overview & Revenue Model

Company Description

Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.

How the Company Makes Money

Azenta generates revenue through multiple streams, primarily from its biobanking and genomic services. The company charges clients for sample storage, management, and processing, which are essential for research and clinical trials. Additionally, Azenta offers genomic analysis services, including sequencing and data interpretation, which are crucial for clients engaged in genetic research and diagnostics. Significant partnerships with pharmaceutical companies, research institutions, and academic organizations enhance its revenue generation, as these collaborations often lead to long-term contracts and increased service utilization. Furthermore, Azenta's expansion into international markets and investment in cutting-edge technologies contribute to its growth and profitability.

Azenta Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Azenta Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 35.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTA, the sentiment is Neutral. The current price of 35.05 is below the 20-day moving average (MA) of 38.82, below the 50-day MA of 36.41, and above the 200-day MA of 31.54, indicating a neutral trend. The MACD of 0.90 indicates Positive momentum. The RSI at 47.33 is Neutral, neither overbought nor oversold. The STOCH value of 27.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AZTA.

Azenta Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
ATRC	73 Outperform	$1.84B	-60.56	-6.11%	―	15.80%	26.94%
AZTA	59 Neutral	$1.79B	-30.65	1.41%	―	-9.49%	58.97%
QDEL	54 Neutral	$1.85B	-1.62	-44.21%	―	-3.43%	38.98%
BLFS	52 Neutral	$1.05B	-325.04	-5.20%	―	-18.82%	92.56%
STAA	46 Neutral	$942.61M	-9.22	-24.65%	―	-32.42%	-540.37%
SMTI	42 Neutral	$196.58M	-5.08	-27.19%	―	30.55%	-340.19%

Azenta Corporate Events

Azenta Shareholders Reaffirm Board, Pay Plans and Auditor

At its annual meeting on January 28, 2026, Azenta, Inc. stockholders voted to re-elect all nominated directors, signaling continued support for the company’s current board composition and governance. Investors also backed, on an advisory basis, the compensation packages for named executive officers, approved an amendment to the 2020 Equity Incentive Plan to add 2,750,000 shares for future equity grants, and ratified the appointment of PricewaterhouseCoopers LLP as Azenta’s independent auditor for the 2026 fiscal year, collectively reinforcing management’s strategic flexibility in incentivizing employees and maintaining auditor continuity for stakeholders.

The most recent analyst rating on (AZTA) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Azenta stock, see the AZTA Stock Forecast page.

Azenta divests B Medical Systems to streamline portfolio

On December 29, 2025, Azenta announced that its affiliate Azenta Germany GmbH has entered into a definitive agreement to sell the company’s Luxembourg-based B Medical Systems business, a global manufacturer and distributor of medical refrigeration devices, to THELEMA S.À R.L. for US$63 million, with the transaction expected to close on or before March 31, 2026. Management described the divestiture as a major step in simplifying Azenta’s portfolio to concentrate on its highest-impact core capabilities, with proceeds earmarked to strengthen the business and support long-term profitable value creation for shareholders, while William Blair and Taylor Wessing advised Azenta on the deal.

The most recent analyst rating on (AZTA) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Azenta stock, see the AZTA Stock Forecast page.

Azenta Announces $250 Million Share Repurchase Program

On December 10, 2025, Azenta, Inc. announced a $250 million share repurchase program authorized by its Board of Directors, effective from December 9, 2025, to December 31, 2028. The program aims to enhance shareholder value and capitalize on stock undervaluation, with repurchases occurring through various compliant methods based on market conditions and other factors. This strategic move is part of Azenta’s capital allocation strategy, which focuses on productivity, organic growth, strategic mergers and acquisitions, and returning capital to shareholders.

The most recent analyst rating on (AZTA) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Azenta stock, see the AZTA Stock Forecast page.